Takeda

TAK on NYSE

Markets rusfertide (Mimrylo), a hepcidin-mimetic peptide for polycythemia vera, under a deal with Protagonist.

Share price

$18.73

Up 28% over 12 months

What analysts expect

Buy

Buy100%

Hold0%

Sell0%

Price target for the next 12 months

6,620 JPYUp 11% compared with the current price

Price now 5,963 JPYAverage targetLowest 5,800 JPY to highest 7,600 JPY

16 analysts. Targets are for the Tokyo-listed share, in yen. One US share (ADR) equals half a Tokyo share. Source: MarketScreener, 20 Oct 2026. Targets are opinions and are often wrong.

Business

Yearly revenue: $28B
Yearly profit: Loss $1B
Company value: $59B

Revenue and profit for the last twelve months reported.

Peptides in this book

RusfertidePrescription

Prices are delayed and figures rounded. Not investment advice.